Gliomas (neoplasms in the brain) are especially aggressive malignant forms of a tumor, often resulting in the death of affected patients within one to two years following diagnosis. There is no remedy for gliomas and most possible treatments provide just minor symptomatic relief.
A review of the recent scientific literature reveals various preclinical studies and one pilot clinical research showing cannabinoids’ (THCA, THC, CBDA, CBD, CBN…) ability to act as antineoplastic factors, particularly on glioma cell lines.
Writing in the September 1998 issue of the journal FEBS Letters, researchers at Madrid’s Complutense University, School of Biology, first published that delta-9-tetrahydrocannabinol induced apoptosis (programmed cell death) in glioma cells in culture. Researchers followed up their initial findings in 2000, reporting that the treatment of both Tetrahydrocannabinol (THC) and the synthetic cannabinoid agonist WIN 55,212-2 “induced a considerable regression of destructive gliomas” in animals. Researchers again affirmed cannabinoids (THCA, THC, CBDA, CBD, CBN…)’ capability to inhibit neoplasm increase in animals in 2003.
That same year, Italian researchers at the University of Milan(Università Degli Studi di Milano), Department of pharmacology, Chemotherapy, and Toxicology published that the cannabinoid, cannabidiol (CBD), restrained the growth of different human glioma cell lines in vitro and in vivo in a dose-dependent manner. Writing in the November 2003 problem of the JPET Fast Forward (the Journal of Pharmacology and Experimental Therapeutics Fast Forward), researchers settled, “Non-psychoactive cannabidiol (CBD)… produce[s] an important anti-neoplasm activity together in vivo and in vitro, thus suggesting a potential utilization of cannabidiol (CBD) as an antineoplastic factor.”
In 2004, Guzman and colleagues published that cannabinoids (THCA, THC, CBDA, CBD, CBN…) inhibited glioma neoplasm growth in animals and in human glioblastoma multiforme (GBM) neoplasm samples by altering blood vessel morphology (e.g., VEGF pathways). Writing in the Summer 2004 problem of tumor Research, researchers concluded, “The existing clinical and laboratory findings give a novel pharmacological target for cannabinoid-based treatments.”
Researchers at the CPMC (California Pacific Medical Center Research) Institute announced that the treatment of Tetrahydrocannabinol (THC) on human glioblastoma multiforme cell lines reduced the proliferation of destructive cells and induced cell death more rapidly than did the treatment of WIN 55,212-2. Researchers also remarked that Tetrahydrocannabinol (THC) selectively targeted cancerous cells while neglecting healthy ones in a more thorough way than the synthetic choice. A separate preclinical test published that the combined treatment of Tetrahydrocannabinol (THC) and the pharmaceutical agent temozolomide (TMZ) “enhanced autophagy” (programmed cell death) in brain neoplasms resistant to conventional anti-cancer treatments.
Guzman and colleagues have also published that Tetrahydrocannabinol (THC) treatment decreases recurrent glioblastoma multiforme neoplasm growth in patients diagnosed with recurrent GBM. In the first-ever pilot clinical trial assessing the use of cannabinoids (THCA, THC, CBDA, CBD, CBN…) and GBM, researchers found that the intratumoral treatment of Tetrahydrocannabinol (THC) was associated with reduced neoplasm cell proliferation in two of nine subjects. “The fair safety profile of Tetrahydrocannabinol (THC), together with its possible antiproliferative action on neoplasm cells published here and in other studies, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids (THCA,THC, CBDA, CBD, CBN…),” researchers concluded. Several additional researchers have also recently called for further exploration of cannabis-based therapies for the treatment of glioma. A separate trial report, written in 2011 in the journal of the ISPN (International Society for Pediatric Neurosurgery), also confirmed the automatically regression of residual brain neoplasms in 2 kids coinciding with the subjects utilize of cannabis.
In addition to cannabinoids (THCA,THC, CBDA, CBD, CBN…)’ ability to moderate glioma cells, separate studies demonstrate that cannabinoids (THCA,THC, CBDA, CBD, CBN…) and endocannabinoids (THCA,THC, CBDA, CBD, CBN…) can also inhibit the proliferation of other various tumor cell lines, including breast cancer, prostate cancer, colorectal cancer, gastric adenocarcinoma, skin cancer, leukemia cells, neuroblastoma, lung cancer, uterus cancer, thyroid epithelioma, pancreatic adenocarcinoma, cervical cancer, oral tumor, biliary tract tumor (cholangiocarcinoma) and lymphoma.
Consequently, many experts now believe that cannabinoids (THCA, THC, CBDA, CBD, CBN…) “may represent a new class of anticancer drugs that retard tumor growth, inhibit angiogenesis and the metastatic spreading of cancer cells.